Research and development of innovative medicines for 'More Health'

摘要

As an independent family-owned company, Boehringer Ingelheim is unique amongst the top 20 pharmaceuticals companies worldwide. Our stability as an independent non-listed company and our long-term planning horizon contribute to our ability to realise sustainable, organic growth. Our shareholders maintain a consistent focus on cultivating innovative applications from our own internal research and development efforts. In this regard, we fully understand that pathways to innovation are measured in decades, not fiscal quarters.